Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies

Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to predict the therapeutic effect of ICIs. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohkuma, Ryotaro, Ieguchi, Katsuaki, Watanabe, Makoto, Takayanagi, Daisuke, Goshima, Tsubasa, Onoue, Rie, Hamada, Kazuyuki, Kubota, Yutaro, Horiike, Atsushi, Ishiguro, Tomoyuki, Hirasawa, Yuya, Ariizumi, Hirotsugu, Tsurutani, Junji, Yoshimura, Kiyoshi, Tsuji, Mayumi, Kiuchi, Yuji, Kobayashi, Shinichi, Tsunoda, Takuya, Wada, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698555/
https://www.ncbi.nlm.nih.gov/pubmed/34944745
http://dx.doi.org/10.3390/biomedicines9121929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698555/
https://www.ncbi.nlm.nih.gov/pubmed/34944745
http://dx.doi.org/10.3390/biomedicines9121929

Ejemplares similares